摘要
原发性肝癌是我国常见的恶性肿瘤之一,其发病率位居我国癌症发病率的第4位。肝癌进展迅速且隐匿性强,患者确诊时往往已处于中晚期,错过最佳治疗时机。2007年以来,索拉菲尼的问世标志着肝癌靶向治疗时代的来临,但机体的耐药性和药物不良反应限制了其使用。近年来,免疫检查点的发现则为中晚期肝癌患者提供了新的治疗选择,免疫检查点抑制剂良好的疗效和安全性使其成为肝癌治疗领域很有潜力的研究方向。
Primary liver cancer is one of the most common malignant tumors and its incidence ranks fourth in the incidence of cancer in China.The progress of liver cancer is rapid and the concealment is strong,and the patients are often in the middle and late stage when they are diagnosed,so they miss the best time for treatment.Since 2007,the advent of sorafinib marks the advent of the era of targeted therapy for liver cancer,but its use is limited by drug resistance and adverse drug reactions.In recent years,the discovery of immune checkpoint provides a new treatment option for patients with advanced liver cancer.Immune checkpoint inhibitor has good efficacy and safety,which makes it a potential research direction in the field of liver cancer treatment.
作者
谢炎
黄亚北
蒋文涛
Xie Yan;Huang Yabei;Jiang Wentao(Tianjin Medical University First Center Clinical College,Tianjin 300070,China;Department of Liver Transplantation,Tianjin First Center Hospital,Tianjin 300070,China;Tianjin Key Laboratory for Organ Transplantation,Tianjin 300070,China;Key Laboratory of Transplantation Medicine,Chinese Academy of Medical Sciences,Tianjin 300070,China)
出处
《肝癌电子杂志》
2022年第1期65-70,共6页
Electronic Journal of Liver Tumor
基金
国家自然科学基金(81870444)
天津市自然科学基金(20JCYBJC01010)
天津市卫生健康委员会面上项目(ZC20100)。
关键词
肝癌
免疫检查点抑制剂
免疫疗法
联合疗法
Hepatic carcinoma
Immune checkpoint inhibitor
Immunotherapy
Combined therapy
